Zogenix, Inc.

ZGNX

시가총액 US$15억

소개: Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.

직원 수: 327